

Remarks

Currently Claims 1-8, 11-13, 17 and 19-21 are pending.

Please add new claims 19-21 as follows.

Claims 9-10, 14-16 and 18 are canceled. Claims 1, 3-6, 8 and 11-13 are amended herein. Claims 1 and 4 are amended to change "represents" to "is." Claims 3, 5-6, 8 and 11-13 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 11-13 are further amended to recite "human" subject in a separate claim, namely claims 19-21, respectively. Claims 8 and 11-13 are further amended to remove the duplicative recitation "derivatives thereof" inasmuch as that recitation appears in claim 1 from which those claims depend. The amendments do not narrow the scope of the claims and are not being made for reasons of patentability. No new matter is added.

The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Notice of Co-Pending Applications

The Examiner is respectfully requested to take note of the following co-pending applications which are commonly-owned with the instant application:

Serial No.	Filing Date
10/508761	22 Sep 04
10/516230	29 Nov 04

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Robert H. Brink  
Attorney for Applicants  
Registration No. 36,094

Date: 28 April, 2005  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988